TriangleNCT00295503 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up 100 months
What was measured
overall survival was measured from time of initiation of treatment to death from any cause
Groups in this outcome
Cisplatin, Pemetrexed and Bevacizumab
cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
| Group | Source count |
|---|---|
| Cisplatin, Pemetrexed and Bevacizumab | 52 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Cisplatin, Pemetrexed and Bevacizumab | 14.8 | Not reported | 10.0 | 17.0 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 10.0
- upper Limit
- 17.0
- value
- 14.8
- denoms
- counts
- group Id
- OG000
- value
- 52
- units
- Participants
- description
- overall survival was measured from time of initiation of treatment to death from any cause
- dispersion Type
- 95% Confidence Interval
- groups
- description
- cisplatin 75 mg/m2, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg IV every 3 weeks
- id
- OG000
- title
- Cisplatin, Pemetrexed and Bevacizumab
- param Type
- MEDIAN
- reporting Status
- POSTED
- time Frame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up 100 months
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice